Related references
Note: Only part of the references are listed.Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years
Stefan Faderl et al.
LEUKEMIA RESEARCH (2010)
Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
Julio Delgado et al.
BLOOD (2009)
Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
Francesc Bosch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Kenneth A. Foon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Transplantation in Chronic Lymphocytic Leukemia: Timing and Expectations
Simon Hallam et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Early Treatment of High-Risk Chronic Lymphocytic Leukemia With Alemtuzumab and Rituximab
Clive S. Zent et al.
CANCER (2008)
Minimal residual disease assessment in chronic lymphocytic leukaemia
Hazem A. Sayala et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Neil E. Kay et al.
BLOOD (2007)
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:: Results of a phase II trial
T Elter et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
KR Rai et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia
B Kennedy et al.
BLOOD (2002)
Share Paper
